Skip to main content

Table 1 Characteristics of patients

From: Effects of endoscopic injection sclerotherapy for esophagogastric varices on portal hemodynamics and liver function

 

All (n = 58)

Increased Group (n = 38)

Decreased group (n = 20)

p*

Age (years)

65.5 (54.5–71.0)

60.0 (52.0–68.0)

69.5 (65.0–75.0)

0.0023

Gender (male/female)

38/20

29/9

9/11

0.0478

Etiology of liver disease

HCV-LC

19

9

10

0.0511

HBV-LC

2

2

0

–

Alcohol-LC

20

16

4

0.0954

HCV + Alcohol-LC

6

4

2

0.9630

NASH (NBNC)-LC

6

4

2

0.9630

PBC-LC

1

0

1

–

AIH-LC

2

2

0

–

Non-cirrhosis

2

1

1

0.6600

Liver function

AST (U/L)

42.0 (34.0–49.0)

37.0 (31.0–49.0)

44.5 (35.3–48.0)

0.4007

ALT (U/L)

26.0 (17.0–36.0)

24.0 (16.0–36.5)

26.5 (21.3–30.8)

0.7242

Platelet count (× 104/μL)

8.1 (5.6–10.7)

7.8 (5.8–10.2)

9.6 (5.5–12.0)

0.3560

Albumin (g/dL)

3.4 (3.2–4.0)

3.6 (3.3–4.1)

3.3 (3.1–3.5)

0.0512

Total Bilirubin (mg/dL)

1.0 (0.8–1.3)

0.9 (0.8–1.0)

1.1 (0.9–2.0)

0.1206

Prothrombin time (%)

70.0 (65.0–77.3)

70.0 (65.5–74.0)

71.2 (65.0–78.0)

0.7151

Creatinine (mg/dL)

0.72 (0.65–0.88)

0.78 (0.69–0.93)

0.71 (0.62–0.81)

0.1666

Ammonia (μg/dL)

61.0 (49.0–76.0)

64.5 (51.0–73.8)

59.0 (49.0–119.0)

0.7755

ICG-R15 (%)

30.0 (20.0–37.0)

27.0 (18.5–33.0)

36.0 (26.5–42.0)

0.0170

FIB4 index

5.87 (4.66–9.11)

6.18 (4.72–9.00)

5.62 (4.76–10.62)

0.9256

Child–Pugh (CP) class (A /B) (CP-A;%)

35/21 (60.3)

26/11 (70.3)

9/10 (47.4)

0.1113

Child–Pugh (CP) score (5/6/7/8/9)

19/15/13 /7/2

14/11/7/5/0

5/4/6/2/2

–

MELD score

14.9 (13.5–16.2)

15.1 (13.9–15.9)

14.6 (13.5–17.0)

0.7542

Endoscopic findings

Form 1/2/3

5/37/16

2/23/13

3/14/3

–

Red color sign (+/-)

46/12

28/10

18/2

0.3122

Number of EIS sessions (times)

2.0 (1.0–2.0)

2.0 (1.0–2.0)

1.5 (1.0–2.0)

0.8875

Total volume of sclerosant (ml)

15.0 (11.0–20.0)

16.5 (12.0–20.0)

14.0 (10.0–16.0)

0.0656

Complications of portal hypertension

Paraesophageal veins (Para-V) (+/-)

22/36

10/28

12/8

0.0168

Paraumbilical veins (+/-)

21/37

13/25

8/12

0.6827

Gastrorenal shunts (after B-RTO) (+/-)

6/52

4/34

2/18

0.7395

Splenomegaly (over 11 cm) (+/-)**

37/21

23/15

14/6

0.5518

Ascites (+/-)

12/46

9/29

3/17

0.4527

Liver hemodynamics

PVTBF (ml/100 ml/min)

27.1 (22.7–31.2)

25.5 (21.4–28.6)

29.7 (25.3–37.2)

0.0151

HATBF (ml/100 ml/min)

19.4 (14.8–25.1)

19.4 (15.7–25.1)

18.5 (11.7–24.2)

0.2695

THTBF (ml/100 ml/min)

47.5 (39.9–60.7)

45.7 (39.9–54.5)

49.9 (56.3–65.5)

0.3304

P/A ratio

1.4 (1.0–1.9)

1.3 (1.0–1.6)

1.7 (1.1–2.0)

0.0073

  1. All data are expressed as median (first quartile-third quartile)
  2. *Mann–Whitney-U test (Increased Group vs. Decreased group)
  3. **The maximum diameter of spleen length by enhanced computed tomography
  4. ‡IG, increased group; DG, decreased group; NASH, nonalcoholic steatohepatitis; NBNC, non-B non-C; PBC, primary biliary cholangitis; AIH, autoimmune hepatitis; AST, aspartate aminotransferase; ALT, alanine aminotransferase, ICG-R15, indocyanine green retention at 15 min; FIB4 index, fibrosis-4; MELD, Model for End-Stage Liver Disease; EIS, endoscopic injection sclerotherapy; B-RTO, balloon-occluded retrograde transvenous obliteration; PVTBF, portal venous tissue blood flow; HATBF, hepatic arterial tissue blood flow; THTBF, total hepatic tissue blood flow; and P/A ratio, PVTBF/HATBF ratio
Back to article page

BMC Gastroenterology

ISSN: 1471-230X

Contact us